Last Updated: September 28 2022

Policosanol is a mixture of oils from Cuban Cane Sugar; touted as a cholesterol lowering agent, it shows potency at this claim in several studies released from Cuba. Other studies undermine the quality of these, however, and it remains controversial.

Policosanol is most often used for


Policosanol is a term used to refer to a mixture of lipophilic (fat-soluble) compounds derived from the waxy coating of Cuban Cane Sugar. It has been used frequently to treat high cholesterol levels, and several studies claim that it does so with a potency rivaling statin therapy. The studies in question all appear to originate from Cuba, and when all studies are looked at collectively yet exclude Cuba the 100% success rate in Cuba declines to approximately 14% success rates in human trials. Due to this significant schism in the literature coupled with Policosanol being derived from a Cuban export, it is plausible that the scientific literature is suffering from publication bias.

The studies conducted outside of Cuba and those conducted in Cuba use similar participant pools, similar dosing, and at times have used the same sources of Cuban Cane Sugar specifically. The only difference is in the dietary protocol given, but some evidence suggests that this is a plausible explanation for the differences seen.

At this moment in time, publication bias and dietary intervention lead-in period are both plausible explanations for the observed differences. Which is disconcerting, as the latter would mean that policosanol can be as effective as statin therapy whereas the former means it is merely a placebo; a black and white issue with little grey area.

Regardless of source of the study or context, however, policosanol usage appears to be very safe; no side-effects have been reported in human interventions from Cuba or elsewhere and blatant overdoses in research animals fail to exert toxicity.

What else is Policosanol known as?
Note that Policosanol is also known as:
  • Cane Sugar Extract
Policosanol should not be confused with:
  • Octacosanol (major constituent)
Dosage information

The standard supplemental dosage of policosanol is 5-10mg taken twice daily (for a daily total of 10-20mg), although due to the state of the research on this supplement it is not sure if it is bioactive in this range.

Supplements Demystified: Get Our Unbiased, Evidence-Based Guide

Examine Database: Policosanol
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

4.^Adhikari P, Hwang KT, Park JN, Kim CKPolicosanol content and composition in perilla seedsJ Agric Food Chem.(2006 Jul 26)
6.^Irmak S, Dunford NTPolicosanol contents and compositions of wheat varietiesJ Agric Food Chem.(2005 Jul 13)
7.^Cherif AO, Ben Messaouda M, Kaabi B, Boukhchina S, Pepe C, Kallel HComparison of the Concentrations of Long-Chain Alcohols (Policosanol) in Three Tunisian Peanut Varieties ( Arachis hypogaea L.)J Agric Food Chem.(2010 Nov 9)
9.^Caligiani A, Bonzanini F, Palla G, Cirlini M, Bruni RCharacterization of a potential nutraceutical ingredient: pomegranate (Punica granatum L.) seed oil unsaponifiable fractionPlant Foods Hum Nutr.(2010 Sep)
10.^Ravindranath SV, Uppugundla N, Lay JO, Clausen EC, Wilkins M, Ingraham RG, West C, Wu Y, Carrier DJPolicosanol, alpha-tocopherol, and moisture content as a function of timing of harvest of Switchgrass (Panicum virgatum L.)J Agric Food Chem.(2009 May 13)
12.^Banerjee S, Ghoshal S, Porter TDActivation of AMP-kinase by policosanol requires peroxisomal metabolismLipids.(2011 Apr)
13.^Cabrera L, González V, Uribarri E, Sierra R, Laguna A, Magraner J, Mederos D, Velázquez CStudy of the stability of tablets containing 10 mg of policosanol as active principleBoll Chim Farm.(2002 May-Jun)
14.^Cabrera L, Rivero B, Magraner J, Sierra R, González V, Uribarri E, Laguna A, Cora M, Tejeda Y, Rodríguez E, Velázquez CStability studies of tablets containing 5 mg of policosanolBoll Chim Farm.(2003 Sep)
16.^Marinangeli CP, Kassis AN, Jain D, Ebine N, Cunnane SC, Jones PJComparison of composition and absorption of sugarcane policosanolsBr J Nutr.(2007 Feb)
18.^Menéndez R, Marrero D, Más R, Fernández I, González L, González RMIn vitro and in vivo study of octacosanol metabolismArch Med Res.(2005 Mar-Apr)
21.^Carling D, Sanders MJ, Woods AThe regulation of AMP-activated protein kinase by upstream kinasesInt J Obes (Lond).(2008 Sep)
23.^Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto GRegulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanolLipids.(2009 Oct)
25.^Ferrer A, Caelles C, Massot N, Hegardt FGActivation of rat liver cytosolic 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase by adenosine 5'-monophosphateBiochem Biophys Res Commun.(1985 Oct 30)
27.^Menendez R, Fernandez SI, Del Rio A, Gonzalez RM, Fraga V, Amor AM, Mas RMPolicosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblastsBiol Res.(1994)
28.^Menéndez R, Amor AM, Rodeiro I, González RM, González PC, Alfonso JL, Más RPolicosanol modulates HMG-CoA reductase activity in cultured fibroblastsArch Med Res.(2001 Jan-Feb)
29.^Menendez R, Amor AM, Gonzalez RM, Fraga V, Mas REffect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic ratsBiol Res.(1996)
30.^Menéndez R, Arruzazabala L, Más R, Del Río A, Amor AM, González RM, Carbajal D, Fraga V, Molina V, Illnait JCholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein dietBr J Nutr.(1997 Jun)
33.^Castaño G, Más R, Fernández JC, Fernández L, Illnait J, López EEffects of policosanol on older patients with hypertension and type II hypercholesterolaemiaDrugs R D.(2002)
34.^Castaño G, Mas R, Fernández L, Illnait J, Gámez R, Alvarez EEffects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind studyInt J Clin Pharmacol Res.(2001)
35.^Castaño G, Más R, Fernández JC, Illnait J, Fernández L, Alvarez EEffects of policosanol in older patients with type II hypercholesterolemia and high coronary riskJ Gerontol A Biol Sci Med Sci.(2001 Mar)
36.^Pons P, Rodríguez M, Robaina C, Illnait J, Más R, Fernández L, Fernández JCEffects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatmentInt J Clin Pharmacol Res.(1994)
37.^Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, Diaz E, Castano GA two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemiaInt J Clin Pharmacol Res.(1995)
38.^Torres O, Agramonte AJ, Illnait J, Más Ferreiro R, Fernández L, Fernández JCTreatment of hypercholesterolemia in NIDDM with policosanolDiabetes Care.(1995 Mar)
39.^Batista J, Stüsser R, Saéz F, Pérez BEffect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot studyInt J Clin Pharmacol Ther.(1996 Mar)
40.^Más R, Castaño G, Illnait J, Fernández L, Fernández J, Alemán C, Pontigas V, Lescay MEffects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factorsClin Pharmacol Ther.(1999 Apr)
41.^Castaño G, Más R, Fernández L, Fernández JC, Illnait J, López LE, Alvarez EEffects of policosanol on postmenopausal women with type II hypercholesterolemiaGynecol Endocrinol.(2000 Jun)
42.^Castaño G, Más R, Arruzazabala ML, Noa M, Illnait J, Fernández JC, Molina V, Menéndez AEffects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patientsInt J Clin Pharmacol Res.(1999)
44.^Castaño G, Menéndez R, Más R, Amor A, Fernández JL, González RL, Lezcay M, Alvarez EEffects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitusInt J Clin Pharmacol Res.(2002)
45.^Castaño G, Mas R, Fernández L, Illnait J, Mesa M, Alvarez E, Lezcay MComparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemiaDrugs Aging.(2003)
47.^Castaño G, Mas R, Gámez R, Fernández J, Illnait J, Fernández L, Mendoza S, Mesa M, Gutiérrez JA, López EConcomitant use of policosanol and beta-blockers in older patientsInt J Clin Pharmacol Res.(2004)
48.^Fernández S, Más R, Gamez R, Diaz A, Fernández J, Deibis Orta S, Illnait J, Castańo G, Mendoza S, Valdés F, Alvarez EA pharmacological surveillance study of the tolerability of policosanol in the elderly populationAm J Geriatr Pharmacother.(2004 Dec)
49.^Castaño G, Más R, Fernández L, Illnait J, Mendoza S, Gámez R, Fernández J, Mesa MA comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded studyDrugs Exp Clin Res.(2005)
51.^Alcocer L, Fernández L, Campos E, Más RA comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemiaInt J Tissue React.(1999)
53.^Francini-Pesenti F, Beltramolli D, Dall'acqua S, Brocadello FEffect of sugar cane policosanol on lipid profile in primary hypercholesterolemiaPhytother Res.(2008 Mar)
54.^Francini-Pesenti F, Brocadello F, Beltramolli D, Nardi M, Caregaro LSugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: a double blind, controlled studyComplement Ther Med.(2008 Apr)
55.^Lin Y, Rudrum M, van der Wielen RP, Trautwein EA, McNeill G, Sierksma A, Meijer GWWheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrationsMetabolism.(2004 Oct)
59.^Dulin MF, Hatcher LF, Sasser HC, Barringer TAPolicosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trialAm J Clin Nutr.(2006 Dec)
60.^Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GBComparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trialAm Heart J.(2006 Nov)
62.^Swanson B, Keithley JK, Sha BE, Fogg L, Nerad J, Novak RM, Adeyemi O, Spear GTPolicosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trialAltern Ther Health Med.(2011 Mar-Apr)
63.^Menéndez R, Más R, Amor AM, González RM, Fernández JC, Rodeiro I, Zayas M, Jiménez SEffects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitroBr J Clin Pharmacol.(2000 Sep)
65.^Arruzazabala ML, Molina V, Mas R, Fernández L, Carbajal D, Valdés S, Castaño GAntiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patientsClin Exp Pharmacol Physiol.(2002 Oct)
66.^Valdes S, Arruzazabala ML, Fernandez L, Más R, Carbajal D, Aleman C, Molina VEffect of policosanol on platelet aggregation in healthy volunteersInt J Clin Pharmacol Res.(1996)
67.^Arruzazabala ML, Valdés S, Más R, Fernández L, Carbajal DEffect of policosanol successive dose increases on platelet aggregation in healthy volunteersPharmacol Res.(1996 Nov-Dec)
69.^Carbajal D, Arruzazabala ML, Valdés S, Más REffect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteersProstaglandins Leukot Essent Fatty Acids.(1998 Jan)
70.^Arruzazabala ML, Más R, Molina V, Carbajal D, Mendoza S, Fernández L, Valdés SEffect of policosanol on platelet aggregation in type II hypercholesterolemic patientsInt J Tissue React.(1998)
71.^Stüsser R, Batista J, Padrón R, Sosa F, Pereztol OLong-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patientsInt J Clin Pharmacol Ther.(1998 Sep)
72.^Castaño G, Más R, Roca J, Fernández L, Illnait J, Fernández JC, Selman EA double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudicationAngiology.(1999 Feb)
74.^Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, Matthias A, Lehmann RP, McLachlan AJPharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjectsBr J Clin Pharmacol.(2010 May)
76.^Castaño G, Fernández L, Mas R, Illnait J, Gámez R, Mendoza S, Mesa M, Fernández JEffects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemiaDrugs R D.(2005)
77.^Fontani G, Lodi L, Migliorini S, Corradeschi FEffect of omega-3 and policosanol supplementation on attention and reactivity in athletesJ Am Coll Nutr.(2009 Aug)
78.^Fontani G, Maffei D, Lodi LPolicosanol, reaction time and event-related potentialsNeuropsychobiology.(2000)
79.^Re L, Barocci S, Capitani C, Vivani C, Ricci M, Rinaldi L, Paolucci G, Scarpantonio A, León-Fernández OS, Morales MAEffects of some natural extracts on the acetylcholine release at the mouse neuromuscular junctionPharmacol Res.(1999 Mar)
80.^Noa M, Más R, Mendoza S, Gámez R, Mendoza N, González JPolicosanol prevents bone loss in ovariectomized ratsDrugs Exp Clin Res.(2004)
81.^Fisher JE, Rodan GA, Reszka AAIn vivo effects of bisphosphonates on the osteoclast mevalonate pathwayEndocrinology.(2000 Dec)
82.^Arruzazabala ML, Molina V, Carbajal D, Más RD-003 and warfarin interaction on the bleeding time and venous thrombosis experimentally induced in ratsJ Med Food.(2004 Summer)
83.^Molina V, Arruzazabala ML, Carbajal D, Más RSynergistic effect of D-003 and aspirin on experimental thrombosis modelsProstaglandins Leukot Essent Fatty Acids.(2003 May)
85.^Alemán CL, Puig MN, Elías EC, Ortega CH, Guerra IR, Ferreiro RM, Briñis FCarcinogenicity of policosanol in mice: an 18-month studyFood Chem Toxicol.(1995 Jul)
86.^Alemán CL, Más R, Hernández C, Rodeiro I, Cerejido E, Noa M, Capote A, Menéndez R, Amor A, Fraga V, et alA 12-month study of policosanol oral toxicity in Sprague Dawley ratsToxicol Lett.(1994 Jan)
87.^Rodríguez MD, Garcia HEvaluation of peri- and post-natal toxicity of Policosanol in ratsTeratog Carcinog Mutagen.(1998)
88.^Gámez R, Alemán CL, Más R, Noa M, Rodeiro I, García H, Hernández C, Menéndez R, Aguilar CA 6-Month Study on the Toxicity of High Doses of Policosanol Orally Administered to Sprague-Dawley RatsJ Med Food.(2001 Summer)
89.^Rodríguez MD, García HTeratogenic and reproductive studies of policosanol in the rat and rabbitTeratog Carcinog Mutagen.(1994)
90.^Rodríguez-Echenique C, Mesa R, Más R, Noa M, Menéndez R, González RM, Amor AM, Fraga V, Sotolongo V, Laguna AEffects of policosanol chronically administered in male monkeys (Macaca arctoides)Food Chem Toxicol.(1994 Jun)
91.^Alemán CL, Más Ferreiro R, Noa Puig M, Rodeiro Guerra I, Hernández Ortega C, Capote ACarcinogenicity of policosanol in Sprague Dawley rats: a 24 month studyTeratog Carcinog Mutagen.(1994)